Physician profile
James Kim
NPI 1598841447
$2,576.59
in general payments reported to CMS, 2019-2025
18 companies · $1,304 in 2025
The $1,304 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.80 · 2021: $90.28 · 2022: $137 · 2023: $416 · 2024: $544 · 2025: $1,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,069 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,068.52 |
| Education | $195.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $965.20 | 2021-2025 | |
| Janssen Biotech, INC. | $477.83 | 2022-2025 | Stelara, Tremfya |
| Regeneron Healthcare Solutions, INC. | $239.78 | 2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $223.87 | 2024-2025 | Entyvio, Eohilia |
| Celltrion USA INC. | $148.87 | 2024-2025 | Vegzelma |
| Boston Scientific Corporation | $85.80 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.67 | 2023-2024 | Xifaxan |
| Ardelyx, INC. | $67.49 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $60.26 | 2025 | |
| Gilead Sciences, INC. | $35.00 | 2025 | |
| Braintree Laboratories, INC. | $33.17 | 2025 | Suflave, Sutab |
| Ipsen Biopharmaceuticals, INC | $32.74 | 2025 | Iqirvo |
| Pfizer INC. | $30.40 | 2024 | |
| Shield Therapeutics INC | $25.44 | 2025 | |
| Ferring Pharmaceuticals INC. | $20.35 | 2024 | Rebyota |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $17.80 | 2025 | |
| Intercept Pharmaceuticals, INC. | $16.79 | 2025 | |
| Medtronic, INC. | $16.13 | 2025 | Nexpowder |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.